Verve Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ALPHABET INC. | 11/08/2024 | 12.35 M | $59.77 M | 0.00% | 14.66% |
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 7.28 M | $35.22 M | 100.00% | 8.64% |
| MILLENNIUM MANAGEMENT LLC | 11/14/2024 | 4.96 M | $24.02 M | 28.22% | 5.89% |
| STATE STREET CORP | 11/14/2024 | 4.25 M | $20.59 M | 26.98% | 5.05% |
| VANGUARD GROUP INC | 11/13/2024 | 4.01 M | $19.38 M | -23.91% | 4.76% |
| CASDIN CAPITAL, LLC | 11/14/2024 | 4.00 M | $19.34 M | 30.61% | 4.74% |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 11/14/2024 | 2.43 M | $11.74 M | -46.45% | 2.88% |
| SCHONFELD STRATEGIC ADVISORS LLC | 11/14/2024 | 2.41 M | $11.65 M | 100.00% | 2.86% |
| NOVO HOLDINGS A/S | 10/24/2024 | 2.40 M | $11.62 M | 0.00% | 2.85% |
| ARCH VENTURE MANAGEMENT, LLC | 11/14/2024 | 2.01 M | $9.72 M | 0.00% | 2.39% |
| BAKER BROS. ADVISORS LP | 11/14/2024 | 1.69 M | $8.19 M | 0.00% | 2.01% |
| NUVEEN ASSET MANAGEMENT, LLC | 11/14/2024 | 1.67 M | $8.09 M | 106.26% | 1.98% |
| JPMORGAN CHASE & CO | 12/26/2024 | 1.65 M | $7.98 M | -2.57% | 1.96% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 1.60 M | $7.75 M | 2.62% | 1.90% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 11/14/2024 | 1.56 M | $7.55 M | 72.15% | 1.85% |
| FMR LLC | 11/13/2024 | 1.42 M | $6.87 M | 0.27% | 1.68% |
| REDMILE GROUP, LLC | 11/14/2024 | 1.38 M | $6.70 M | -5.47% | 1.64% |
| ECOR1 CAPITAL, LLC | 11/14/2024 | 1.25 M | $6.05 M | 0.00% | 1.48% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 1.05 M | $5.07 M | -18.64% | 1.24% |
| MORGAN STANLEY | 11/14/2024 | 913,191 | $4.42 M | 46.41% | 1.08% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 776,222 | $3.76 M | 64.10% | 0.92% |
| CITADEL ADVISORS LLC | 11/14/2024 | 745,055 | $3.61 M | 46.85% | 0.88% |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 11/14/2024 | 678,625 | $3.28 M | 71.50% | 0.81% |
| BVF INC/IL | 11/14/2024 | 650,000 | $3.15 M | 0.00% | 0.77% |
| BRAIDWELL LP | 11/14/2024 | 623,980 | $3.02 M | 100.00% | 0.74% |
| PALO ALTO INVESTORS LP | 11/14/2024 | 575,817 | $2.79 M | 0.00% | 0.68% |
| RENAISSANCE TECHNOLOGIES LLC | 11/13/2024 | 574,786 | $2.78 M | 21.14% | 0.68% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11/12/2024 | 572,173 | $2.77 M | 28.27% | 0.68% |
| TREXQUANT INVESTMENT LP | 11/12/2024 | 555,502 | $2.69 M | 6.13% | 0.66% |
| VESTAL POINT CAPITAL, LP | 11/14/2024 | 525,000 | $2.54 M | 5.00% | 0.62% |
| DIMENSIONAL FUND ADVISORS LP | 11/07/2024 | 431,769 | $2.09 M | -1.06% | 0.51% |
| TWO SIGMA INVESTMENTS, LP | 11/14/2024 | 430,274 | $2.08 M | -29.17% | 0.51% |
| CORMORANT ASSET MANAGEMENT, LP | 11/14/2024 | 350,000 | $1.69 M | 0.00% | 0.42% |
| WELLINGTON MANAGEMENT GROUP LLP | 11/14/2024 | 347,029 | $1.68 M | -6.54% | 0.41% |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 11/04/2024 | 262,393 | $1.27 M | 8.22% | 0.31% |
| AMERIPRISE FINANCIAL INC | 11/14/2024 | 226,056 | $1.09 M | 25.99% | 0.27% |
| ALGERT GLOBAL LLC | 11/12/2024 | 224,216 | $1.09 M | 63.07% | 0.27% |
| BARCLAYS PLC | 11/19/2024 | 222,919 | $1.08 M | 139.76% | 0.26% |
| JANE STREET GROUP, LLC | 11/15/2024 | 216,901 | $1.05 M | -14.54% | 0.26% |
| BANK OF NEW YORK MELLON CORP | 11/12/2024 | 215,240 | $1.04 M | -21.69% | 0.26% |
| RAFFERTY ASSET MANAGEMENT, LLC | 11/13/2024 | 210,956 | $1.02 M | -6.80% | 0.25% |
| ACADIAN ASSET MANAGEMENT LLC | 11/12/2024 | 192,766 | $932,000 | 100.00% | 0.23% |
| TWO SIGMA ADVISERS, LP | 11/14/2024 | 184,600 | $893,464 | -22.66% | 0.22% |
| PDT PARTNERS, LLC | 11/14/2024 | 181,803 | $879,927 | -45.55% | 0.22% |
| IKARIAN CAPITAL, LLC | 11/14/2024 | 170,000 | $822,800 | 100.00% | 0.20% |
| UBS GROUP AG | 11/14/2024 | 164,127 | $794,375 | 53.82% | 0.19% |
| ACUTA CAPITAL PARTNERS, LLC | 11/14/2024 | 146,100 | $707,124 | 100.00% | 0.17% |
| STIFEL FINANCIAL CORP | 11/14/2024 | 131,406 | $636,007 | 14.70% | 0.16% |
| HRT FINANCIAL LP | 11/12/2024 | 126,859 | $613,000 | 100.00% | 0.15% |
| PFM HEALTH SCIENCES, LP | 11/14/2024 | 125,999 | $609,835 | 100.00% | 0.15% |
Verve Therapeutics, Inc.institutional Ownership - FAQ's
During the previous two years, 197 institutional investors and hedge funds held shares of Verve Therapeutics, Inc.. The most heavily invested institutionals were:
Alphabet Inc.: 12.35 M
BlackRock Funding, Inc. /DE: 7.28 M
MILLENNIUM MANAGEMENT LLC: 4.96 M
STATE STREET CORP: 4.25 M
VANGUARD GROUP INC: 4.01 M
Casdin Capital, LLC: 4 M
89.29% of Verve Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 81.48 M shares in the last 24 months. This purchase volume represents approximately $489.67 M in transactions.